AMGN Amgen Inc.
AMGN Amgen Inc.
Healthcare · Drug Manufacturers - General
Desk view
Market read
Scan convergence 3 scans as of 2026-10-23 3 bull converging
POC $345.72 · VWAP $361.09 · +21.6% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster SVP + 2 others sold $4.1M, Aug 7–13
Coverage
5 watchlists
AMGN Price Structure
Loading timeframes…
Peers
Every watchlist AMGN belongs to, members best 30-day change first — AMGN highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@peptide-economy
@healthcare-scan
@healthcare
@ibb
@biotech-scan
Reported the quarter ending 2026-06-30: revenue $10.05B, diluted EPS $4.37, net income $2.38B (SEC filing, revenue corroborated by the desk's provider cache). Across the print the stock moved +7.6% (close before → first close after).
full note →Against street estimates
How AMGN's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
News (last pull)
Headlines about AMGN from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 16 days ago · Oct 7
AMGN research tape
159 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.